Please provide your email address to receive an email when new articles are posted on . Data published in July in JAMA Ophthalmology showed that 0.01% atropine drops safely curbed myopia progression ...

Childhood myopia progression could be treated with low-dose atropine due to the safety and efficacy displayed in this study. The global prevalence of myopia was estimated to be 30% to 34% in 2020 and ...

A Prescription Drug User Fee Act target date of October 23, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ...

Prior to this research, recent trials conducted primarily in East Asia showed a benefit from .01 percent atropine in slowing myopia. The randomized controlled trial, conducted by the Pediatric Eye ...

Please provide your email address to receive an email when new articles are posted on . Bell reported results from the phase 3 CHAMP clinical study, which evaluated children with –0.5 D to –6 D ...

Use of low-dose atropine eyedrops (concentration 0.01%) was no better than placebo at slowing myopia (nearsightedness) progression and elongation of the eye among children treated for two years, ...

A study conducted at Vanderbilt University Medical Center and 11 other hospitals and practices across the United States shows that use of low-dose atropine eyedrops, commonly used in a higher dose to ...

DEL MAR, Calif.--(BUSINESS WIRE)--Sydnexis, Inc., (www.sydnexis.com), a biopharmaceutical company focused on pediatric progressive myopia (PPM), today announced that the U.S. Food and Drug ...

Children with myopia using 0.05% atropine eye drops had less myopia progression and/or less axial elongation compared with those using placebo or 0.01% atropine, though they had higher rates of ...

Credit: Getty Images. A PDUFA target date of January 31, 2024 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for NVK002 ...